CRITICAL ILLNESS CARE PROGRAM
What is it?
In order to help the community we launched this program where medicine to the critically ill will be offered at a discount, or free, as and when donated medicine becomes available. Therefore, we are soliciting the support of the patient growers who produce flowers, edibles, concentrates, pills, etc. to drop off their donations at Compassionate Care Clinics.
How to sign up?
New or existing patients will need a letter from their treating physician, verifying the critical illness or terminal disease that they may be suffering with. Please bring the original letter so we can put a copy in your file. Each letter is good for one year from the date of the letter.
What benefit will I get as a member of Critical Illness Care patient program?
We will give you a 15% credit on all flowers, edibles, tinctures, concentrates, etc. to try and help with some of the cost. All taxes are paid by Compassionate Care Clinics and are included in the suggested donation amounts.
Upon receiving donated supplies, our goal is to provide the medicine to you at any amount of donation you’d be able to offer upon your visit.
How long will this program last?
Depending upon donations and support of the medical marijuana community, we’d love to keep this program going as long as possible*.
*We reserve the right to amend, add or change the guidelines of the Critical Illness Care program at any time, or to terminate the program entirely without prior notice.
PATENTS GRANTED FOR MEDICINAL CANNABIS:
US 6630507B1. Cannabinoids as antioxidants and neuroprotectants. “Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention.” ORIGINAL ASSIGNEE: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES.
US 7285687B2. Cannabinoids. “The compounds are useful for therapy, especially in the treatment of pain, inflammation and autoimmune disease”. ORIGINAL ASSIGNEE VIRGINIA COMMONWEALTH UNIVERSITY, VIRGINIA ; ORGANIX INC., MASSACHUSETTS.
US 4282248A. Pinene derivatives and pharmaceutical compositions containing the same. “The pharmaceutical compositions are of value as central nervous system depressants, as sedatives, as tranquilizers, as anticonvulsant agents, as effective agents against migraine, for the treatment of glaucoma, as antidiarrheal agents and as antiinflammatory agents. The invention also relates to a process for the production of the above compounds and pharmaceutical compositions.” OWNER NAME: PLANTEX LTD., INDUSTRIAL ZONE, NETANYA, ISRAEL YISSUM RESEARCH AND DEVELOPMENT COMPANY.
US 7741365B2. Peripheral cannabinoid receptor (CB2) selective ligands. “There is considerable interest in developing cannabinoid analogs possessing high affinity for the CB2 receptor. Cannabinoid analogs that preferentially stimulate the CB2 receptor, directly or indirectly, can provide clinically useful effects without affecting the subject's central nervous system. Such analogs may offer a rational therapeutic approach to a variety of disease states.” OWNER NAME: UNIVERSITY OF CONNECTICUT,CONNECTICUT.
US 4758597A. Carenadiol and derivatives. “The present invention relates to new synthetic compounds of the cannabinoid class, specifically carenadiol and its derivatives. This compound and its derivatives have been shown to have biological activity which indicates their usefulness in the treatment of patients with various neurological disorders.” OWNER NAME: UNIVERSITY PATENTS, INC., 1465 POST RD., WESTPORT, MASSACHUSETTS.
US 6563009B1. Vasodilator cannabinoid analogs. “The present invention generally relates to ligands of the mammalian CB receptor family and, more particularly, to cannabidiol and abnormal cannabidiol derivatives that act as antagonists and agonists for non CB1 and non CB2 receptor subgoups and to using these derivatives to treat pathological states arising from abnormal vasoconstriction, blood pressure, and heart rate. The ligands of the present invention elicit beneficial pharmacological effects associated with cannabinoid receptor stimulation without the concomitant psychoactive effects associated with previously described cannabinoid receptor family ligands. Accordingly, the compounds of the present invention provide useful pharmacologic compounds which may be administered to treat various disease states without the deleterious side effects associated with previous cannabinoid receptor compounds. The invention thus also relates to methods for the treatment of disease states which may be alleviated by drug-induced vasodilation such as, e.g., high blood pressure, hypertension, coronary artery disease, and peripheral vascular disease. Additionally, the compounds of the present invention may be utilized in labeled and unlabelled form to identify the non CB1 and non CB2 receptors that are the molecular site(s) of action of these compounds and the parental cannabinoid and abnormal cannabinoid ligands”. OWNER NAME: VIRGINIA COMMONWEALTH UNIVERSITY, VIRGINIA.
WO 2009013506A1. Cannabidiol for use in the treatment of transmissible neurodegenerative conditions. “ The present invention relates to the use of cannabidiol for use in the prevention or treatment of neurodegenerative conditions. Preferably the neurodegenerative condition to be prevented or treated is prion disease. Neurodegenerative conditions can be described as the progressive damage or death of neurones. Neurones are nerve cells in the brain whose primary function is to assist in the memory process.
humans prion diseases are characterised by loss of motor control;
dementia; paralysis wasting and eventually death; typically
WO 2008050344A2. Treatment of hepatic encephalopathy and liver cirrhosis. “The compounds D9-tetrahydrocannabinol (THC), cannabidiol (CBD) and capsaicin are useful for prevention, treatment, or both, of hepatic encephalopathy. The compounds capsaicin, 2-arachidonoylglycerol (2-AG), HU-308 and cannabidiol are useful for prevention, treatment, or both, of liver cirrhosis.” YISSUM RES DEV CO.
WO 2010012506A1. Cannabinoids for use in treating or preventing cognitive impairment and dementia. “THC was found to exhibit marked immunosuppressive effects on macrophages, natural killer (NK) cell activity and T lymphocytes. These effects include suppression of mitogen-stimulated proliferation, interleukin (IL)-2 production, T cell-dependent antibody responses and inhibition of macrophage secretion of the proinflammatory cytokine tumor necrosis factor-α (TNF-α). Furthermore, THC was also reported to regulate the Thl-/Th2-type cytokine balance in activated human T cells polarizing the immune response towards a Th2 phenotype. Inhibition of Thl-type cytokines and/or propagation of a Th2-type response are considered to be beneficial in various inflammatory diseases, suggesting cannabinoids as promising agents in the treatment of such disorders.”
WO 2005120478 A1. Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis. “The invention relates to the use of a combination of cannabinoids for the treatment of pain, inflammation and/or disease modification in arthritis. Preferably the cannabinoids are selected from cannabidiol (CBD) or cannabidivarin (CBDV) and delta-9-tetrahydrocannabinol (THC) or tetrahydrocannabinovarin (THCV). More preferably the cannabinoids are in a predefined ratio by weight of less than or equal to 19:1 of CBD or CBDV to THC or THCV.” GW PHARMA LTD.
US20140039043 A1 Pharmaceutical compositions comprising cannabigerol (CBG). “ The naturally
occurring cannabinoid CBG is a precursor to the major cannabinoids CBD, CBC and THC and as such
is rarely found in cannabis plants in any significant concentration. As such this cannabinoid was not thought to possess pharmacological properties. Surprisingly the applicants have found that cannabigerol (CBG) and cannabigerol type compounds (including cannabigerol propyl analogue (CBGV)) and derivatives thereof, are useful in the treatment of mood disorders, particularly depression.” ORIGINAL ASSIGNEE: GW PHARMA LIMITED.
WO2013076487 Phytocannabinoids for use in the treatment of intestinal inflammatory diseases. “The present invention relates to one or more of the phytocannabinoids tetrahydrocannabivarin (THCV); cannabigerol (CBG); cannabichromene (CBC); and cannabidivarin (CBDV) for use in the treatment of intestinal inflammatory diseases. Preferably the intestinal inflammatory disease is either ulcerative colitis or Crohn's disease.” APPLICANTS: GW PHARMA LIMITED.
14) WO2012160358 Cannabinoids for use in the treatment of neuropathic pain. “The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and / or purified from cannabis plant extracts. APPLICANTS: GW PHARMA LIMITED.
WO2012144892 Medical use for acidic cannabinoids. “The invention relates to acidic cannabinoids as defined in the specification for use in increasing the natural resistance of an animal, for use in enhancing cellular resistance, for use in therapy of diabetes, for use in therapy of atherosclerosis, reduce the decline in stress response found in ageing or for use in decreasing the necessity for antibiotic treatment. ` Preferably said acidic cannabinoid is selected from the group consisting of Δ9-tetrahydrocannabinolic acid or THC acid (THCA), cannabidiolic acid (CBD-A), cannabidiol (CBD), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabinolic acid (CBN-A) and cannabinol (CBN), cannabichromenic acid (CBC-A) and cannabichromene (CBC).” APPLICANTS: FYTAGORAS B.V.
WO2013057487 Phytocannabinoids for use in the treatment of breast cancer. “ The present invention relates to phytocannabinoids for use in the treatment of a breast cancer. In a first embodiment the invention relates to an oral presentation of tetrahydrocannabinol (THC) for use in the treatment of aggressive breast cancer, characterised by overexpression of the Her2 gene. In a second embodiment the invention relates to the phytocannabinoid cannabidiol (CBD) for use in the treatment of aggressive breast cancer, characterised by overexpression of the Her2 gene. In a third embodiment the invention relates to the combination of the phytocannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) for use in the treatment of breast cancer or to treat, prevent or to reduce the risk of a cancer metastasising. APPLICANTS: GW PHARMA LIMITED; OTSUKA PHARMACEUTICAL CO., LIMITED.
EP2609928 (European patent): Use of cannabinoids in combination with an anti-psychotic medicament. “The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication.” APPLICANTS; GW PHARMA LTD: OTSUKA PHARMA CO LTD.
WO2013098402 Pharmaceutical combination of fingolimod and nabiximols. “This invention is related to single unit formulation of fingolimod or pharmaceutically acceptable salts thereof in combination with nabiximols mostly composed of cannabidiol (CBD) type compound or derivative thereof and tetrahydrocannabinol (THC) type compound or derivative thereof in treatment of multiple sclerosis. APPLICANTS: DEVA HOLDING ANONIM SIRKETI [TR/TR]